The financial services corporation said it has a negative outlook for the PBM industry this year, particularly for smaller, subscale PBMs.
Four key takeaways from the report:
- The risk for legislation that could hinder the PBM industry is significantly reduced in 2020, because it is an election year, according to the agency.
- S&P doesn’t expect proposals that would ban rebates — the discounts drugmakers pay to PBMs — to return anytime soon. In addition, S&P thinks there is limited political appetite to target spread pricing with legislation, as the Congressional Budget Office projected only $1 billion in savings in 10 years with limiting the tactic. Spread pricing occurs when PBMs charge health insurers more for a drug than it reimburses a pharmacy to dispense the drug.
- Middle-market PBMs will likely consolidate to keep up with their larger peers like CVS Caremark, OptumRx and Express Scripts, S&P said.
- The agency also expects negative political rhetoric to emerge about PBMs during the 2020 presidential election.
More articles on pharmacy:
340B has minimal effect on health spending, study finds
Amazon files ‘Amazon Pharmacy’ trademarks in 3 more countries
Former Insys CEO gets 30 months in prison
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.